Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC-0111 and Gemcitabine in CAIX-positive mPDAC
NCT03450018Phase 2Terminated
- Sponsor
- BC Cancer
- Start
- Jan 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SLC-0111 in pancreatic adenocarcinoma (PDAC), sponsored by BC Cancer. Started Jan 2019; status: terminated.
02
Drugs
SLC-0111
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03450018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450018.